New antibody combo aims to flush out hidden HIV

NCT ID NCT07217379

Recruiting now Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times

Summary

This early-stage study tests whether two experimental antibodies (MGD014 and MGD020) are safe in people with HIV who are on standard antiretroviral therapy. Some participants also receive a drug called Vorinostat to help expose hidden HIV, or temporarily stop their HIV meds. The goal is to see if the antibodies can help control the virus, not cure it. 24 adults will take part for about 8 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kenya Medical Research Institute/Walter Reed Project
NOT_YET_RECRUITING

Kericho, Kenya

Contact
Moi University Clinical Research Center
NOT_YET_RECRUITING

Eldoret, Kenya

Contact
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States

Contact

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

HIV (HUMAN IMMUNODEFICIENCY VIRUS)